These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 23819695)

  • 61. Practical and robust test for comparing binomial proportions in the randomized phase II setting.
    Attwood K; Park S; Hutson AD
    Pharm Stat; 2022 Mar; 21(2):361-371. PubMed ID: 34626075
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Bayesian enhancement two-stage design with error control for phase II clinical trials.
    Jin H; Yin G
    Stat Med; 2020 Dec; 39(29):4452-4465. PubMed ID: 32854163
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Bayesian single-to-double arm transition design using both short-term and long-term endpoints.
    Xu T; Shi H; Lin R
    Pharm Stat; 2023; 22(4):588-604. PubMed ID: 36755420
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Optimal adaptive two-stage designs for early phase II clinical trials.
    Shan G; Wilding GE; Hutson AD; Gerstenberger S
    Stat Med; 2016 Apr; 35(8):1257-66. PubMed ID: 26526165
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Sample size calculation in randomised phase II selection trials using a margin of practical equivalence.
    Dehbi HM; Hackshaw A
    Trials; 2020 Mar; 21(1):301. PubMed ID: 32228674
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A Bayesian-frequentist two-stage single-arm phase II clinical trial design.
    Dong G; Shih WJ; Moore D; Quan H; Marcella S
    Stat Med; 2012 Aug; 31(19):2055-67. PubMed ID: 22415966
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Optimal two-stage designs for single-arm phase II oncology trials with two binary endpoints.
    Kunz CU; Kieser M
    Methods Inf Med; 2011; 50(4):372-7. PubMed ID: 21057719
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A literature review of applied adaptive design methodology within the field of oncology in randomised controlled trials and a proposed extension to the CONSORT guidelines.
    Mistry P; Dunn JA; Marshall A
    BMC Med Res Methodol; 2017 Jul; 17(1):108. PubMed ID: 28720094
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Group sequential adaptive designs in series of time-to-event randomised trials in rare diseases: A simulation study.
    Bayar MA; Le Teuff G; Koenig F; Le Deley MC; Michiels S
    Stat Methods Med Res; 2020 Jun; 29(6):1483-1498. PubMed ID: 31354106
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Curtailed two-stage design for comparing two arms in randomized phase II clinical trials.
    Chen CM; Chi Y; Chang HM
    J Biopharm Stat; 2018; 28(5):939-950. PubMed ID: 29355457
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Bayesian adaptive randomized trial design for patients with recurrent glioblastoma.
    Trippa L; Lee EQ; Wen PY; Batchelor TT; Cloughesy T; Parmigiani G; Alexander BM
    J Clin Oncol; 2012 Sep; 30(26):3258-63. PubMed ID: 22649140
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Bayesian adaptive decision-theoretic designs for multi-arm multi-stage clinical trials.
    Bassi A; Berkhof J; de Jong D; van de Ven PM
    Stat Methods Med Res; 2021 Mar; 30(3):717-730. PubMed ID: 33243087
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Comparing oncology clinical programs by use of innovative designs and expected net present value optimization: Which adaptive approach leads to the best result?
    Parke T; Marchenko O; Anisimov V; Ivanova A; Jennison C; Perevozskaya I; Song G
    J Biopharm Stat; 2017; 27(3):457-476. PubMed ID: 28281911
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Data-driven treatment selection for seamless phase II/III trials incorporating early-outcome data.
    Kunz CU; Friede T; Parsons N; Todd S; Stallard N
    Pharm Stat; 2014; 13(4):238-46. PubMed ID: 24789367
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Inclusion of non-inferiority analysis in superiority-based clinical trials with single-arm, two-stage Simon's design.
    Sampayo-Cordero M; Miguel-Huguet B; Pérez-García J; Páez D; Guerrero-Zotano ÁL; Garde-Noguera J; Aguirre E; Holgado E; López-Miranda E; Huang X; Malfettone A; Llombart-Cussac A; Cortés J
    Contemp Clin Trials Commun; 2020 Dec; 20():100678. PubMed ID: 33336109
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Bayesian sample size determination for phase IIA clinical trials using historical data and semi-parametric prior's elicitation.
    Berchialla P; Zohar S; Baldi I
    Pharm Stat; 2019 Mar; 18(2):198-211. PubMed ID: 30440109
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Randomized phase II/III confirmatory treatment selection design with a change of survival end points: Statistical design of Radiation Therapy Oncology Group 1216.
    Zhang QE; Wu Q; Harari PM; Rosenthal DI
    Head Neck; 2019 Jan; 41(1):37-45. PubMed ID: 30549358
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The clinical effectiveness and cost-effectiveness of rituximab for the first-line treatment of chronic lymphocytic leukaemia: an evidence review of the submission from Roche.
    Main C; Pitt M; Moxham T; Stein K
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):27-32. PubMed ID: 21047488
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Bayesian group sequential designs for phase III emergency medicine trials: a case study using the PARAMEDIC2 trial.
    Ryan EG; Stallard N; Lall R; Ji C; Perkins GD; Gates S
    Trials; 2020 Jan; 21(1):84. PubMed ID: 31937351
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.